Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Cellectar Biosciences, Inc.
Seattle Children's Hospital
National Cancer Institute (NCI)
St. Jude Children's Research Hospital
St. Jude Children's Research Hospital
National Cancer Institute (NCI)
Children's National Research Institute
Baylor College of Medicine
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Seattle Children's Hospital
Seattle Children's Hospital
St. Jude Children's Research Hospital
Milton S. Hershey Medical Center
Baylor College of Medicine
St. Jude Children's Research Hospital
Fudan University
Nationwide Children's Hospital
Memorial Sloan Kettering Cancer Center
Baylor College of Medicine
City of Hope Medical Center
Labcorp Corporation of America Holdings, Inc
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Ann & Robert H Lurie Children's Hospital of Chicago
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Children's National Research Institute
Fudan University
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Emory University
University of Virginia
Bayer
Masonic Cancer Center, University of Minnesota
New York Medical College
Children's National Research Institute
Florida International University
Children's Hospitals and Clinics of Minnesota
MacroGenics
Children's Oncology Group
Dana-Farber Cancer Institute
Emory University
Emory University
Washington University School of Medicine
Nationwide Children's Hospital
Masonic Cancer Center, University of Minnesota